The experience of our team becomes your competitive advantage

Home / Company Overview

What We Do

Our Mission

We are an mRNA CDMO passionate about channeling our technology and the hard work of our team to democratize mRNA R&D by making mRNA readily available to more researchers and companies. We believe that science matters more than ever and that mRNA will open many more doors for science to change the lives of humans everywhere. To fulfill this vision, Vernal is committed to increasing access to high-quality mRNA.

How We Do It

Trusted mRNA Manufacturing

Before building Vernal Biosciences to open up access to this precious material, mRNA, we grew accustomed to the challenges of outsourcing mRNA manufacturing: unreliable supply, variable quality, regulatory confusion, and difficulty scaling the technology and business considerations from research to clinical needs. We will help you eliminate those challenges by leveraging the successes, and even occasional failures we had during our years-long odyssey of outsourcing mRNA. It turns out that outsourcing mRNA can be done properly through a deep alignment with your research and development needs.

Remove guesswork & lengthy development cycles.

Vernal’s platform processes and analytical methods will remove guesswork and lengthy development cycles inherent to many manufacturing processes in the advanced therapeutics field. This will allow Vernal and you to quickly and reliably initiate any additional work unique to your needs, including fine-tuning around your mRNA sequence, target product or target quality profile, or novel use case for your mRNA.

Leverage your company’s value add.

We will collaborate on incentives that encourage both parties to define and rapidly reach project success. Depending on Vernal for your mRNA manufacturing needs will allow you to more effectively resource the areas where you add the most value such as drug discovery, target biology, clinical strategy, and the lives of patients.

VERNAL BIOSCIENCES FOUNDER

Christian Cobaugh, Ph.D.

FOUNDER & CEO

Christian’s leadership in mRNA drug discovery, delivery, process development and quality control, manufacturing, and regulatory matters has been steadily growing since 2013 when he became the first Alexion Pharmaceuticals scientist in partnership with Moderna Therapeutics. Since then, he has led mRNA R&D at Arcturus Therapeutics, Translate Bio, and most recently at Omega Therapeutics as the Vice President of Process Development and Manufacturing.

Read more

He has authored the CMC sections for briefing books, is listed as an inventor on 15 mRNA patent applications, is experienced with LNP-mRNA regulatory interactions, and has developed ICH Q7-compliant quality management systems. Christian holds a Ph.D. in Cell and Molecular Biology from The University of Texas-Austin and post-doc’d for Applied Biosystems in Redwood City, CA. In his spare time, Christian enjoys all that the Green Mountains have to offer, including mountain biking, alpine and Nordic skiing with his family, and volunteering to build and maintain the local trail networks.

MeEt The TEam

Leadership

Grant Henderson, Ph.D.

Head of Manufacturing Science

Read bio

Grant Henderson is responsible for process scale-up of pDNA, mRNA, and LNP-mRNA, and is the interim head of quality control. In addition to leading manufacturing sciences, Grant has been instrumental in facility design, process architecture, and leading the implementation of Vernal’s quality management system. Grant has over 10 years of process engineering experience in small and large molecules at Lonza Biologics and Mylan Technologies with responsibilities ranging from process development to management of regulatory filings.

Lynda Menard, Ph.D.

Head of RNA Sciences

Read bio

Lynda Menard is the Head of RNA Sciences at Vernal Biosciences, where she leads the RUO manufacturing and the team responsible for process innovations. She is also responsible for data architecture and works with clients to define and execute RUO custom orders and process development projects. Lynda joined Vernal Bio from the UVM and prior to that work at Alnylam Pharmaceuticals and Mass Biologics.

Robert Myers

Senior Vice President, Operations

Read bio

Rob is responsible for inventory and materials management, business systems and processes, and operational finance at Vernal. Prior to Vernal, Rob was VP, Business Operations at HTI (now Prolytix) responsible for revenue recognition, forecasting, and CRM. Prior to that he was VP, Business Development and oversaw all marketing and sales activities for both GMP and ISO divisions.

Our Board of Directors

Christian Cobaugh, Ph.D.
Board Member, CEO and Founder of Vernal Biosciences

Christian’s leadership in mRNA drug discovery, delivery, process development and quality control, manufacturing, and regulatory matters has been steadily growing since 2013 when he became the first Alexion Pharmaceuticals scientist in partnership with Moderna Therapeutics. Since then, he has led mRNA R&D at Arcturus Therapeutics, Translate Bio, and most recently at Omega Therapeutics as the Vice President of Process Development and Manufacturing.


David Q. Anderson, Ph.D.
Board Member, General Partner at Ampersand Capital Partners

As General Partner at Ampersand Capital Partners, David brings a wealth of experience from his 20 years in the healthcare industry. Over the last decade, David has supported Ampersand’s portfolio of successful CDMO businesses including BrammerBio, ArrantaBio, Vibalogics, and Genezen.  In addition, David works with other service businesses in the advanced therapies sector including Cellero and Protagene. David holds a B.Sc. in Immunology from the University of Aberdeen, Scotland, a Ph.D. in Tumor Immunobiology from the University of Sheffield, England and an M.B.A. from Babson College, Wellesley, MA.


Gustavo Mahler, Ph.D.
Board Member, Venture Partner at Dynamk Capital

Gustavo Mahler is a Managing Partner at Dynamk Capital and brings a wealth of industry knowledge specifically related to the development and commercialization of biologics. Throughout his career, Gustavo has been involved in all aspects of biomanufacturing including large scale cell culture and protein manufacturing, purification, solid and liquid formulation including aseptic filling, and facility operation under cGMP guidelines. Under his leadership as CEO of AGC Biologics, he successfully supported clients from pre-clinical through commercial production for over 150 biologics programs, while successfully guiding customers through the regulatory approval processes. Gustavo holds a Ph.D. in Biochemistry from the University of Buenos Aires and a Master of Business Administration from the University of Madrid.

Errik Anderson
Board Member, CEO and Founder of Alloy Therapeutics

Errik B. Anderson is the CEO and Founder of Alloy Therapeutics, a biotech ecosystem democratizing access to enabling technologies and services for discovering and developing therapeutic biologics across six modalities including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery. As the CEO of his single-family office, Ulysses Diversified Holdings, and as the previous co-founder and executive of successful biotech companies including Adimab, Compass Therapeutics, Alector, Avitide and Arsanis, Errik brings a breadth of operational and investment experience. Errik received his A.B. from Dartmouth, an M.B.A. from The Tuck School of Business and studied bioengineering at The Thayer School of Engineering.


Pat Sacco
Board Advisor, Principal Consultant Highland Advisors, LLC, and Life Science Technical Operations Executive

Pat Sacco is an accomplished and seasoned biotechnology and life sciences executive with extensive experience in leading technical and general operations, including manufacturing, supply chain, CMC, quality, process sciences, and engineering. He has been recognized for his strategic leadership, especially guiding organizations through periods of rapid growth, change, and transformation, while creating significant capability and driving continuous improvement. Over his 35+ year career, he’s supported and made significant contributions to the development, manufacturing, and commercialization of REPLAGAL®, ELAPRASE®, and VPRIV®. During the past 6 years, as an independent consultant, he has
been actively engaged with several advanced therapy medicinal product (ATMP) biotech companies, CDMOs, and specialized program management clients, providing interim executive management, strategic
advisory support, and technical, operational, and program management expertise and leadership. Previously, he was the SVP of Technical Operations at both Translate Bio and Shire plc (now Takeda, formerly TKT), and prior to that held roles of increasing responsibility at Wyeth Biopharma (formerly Genetics Institute) and Genzyme. Pat holds a Bachelor of Science degree in Chemical Engineering and Biotechnology from Worcester Polytechnic Institute (WPI). He is also a Board member of NewAge Industries Inc., QbDVision, Inc., and Advisory Board Member of Vernal Biosciences Inc.

We’re hiring!

While our platform will rely on breakthrough technology, our future will rely on an awesome team. If you are interested in adding to the success of mRNA medicines, we want to hear from you. We are hiring people, not positions, so please get in touch.

High Purity mRNA

Accelerate your research and development with our RUO catalog and custom mRNA ready for testing in cells and animals.

Contact Us
News & Insights